Celltrion Expands In APAC, Small Molecules Via $278m Takeda Asset Buy
Ongoing Divestments By Japanese Firm
In continuing strategy to shed non-core assets globally, Japanese firm will sell portfolio of selected products in Asia-Pacific to Korean biosimilars giant Celltrion.
